Drug Profile
Research programme: T-cell engagement therapies - Takeda
Alternative Names: COBRATM program - TakedaLatest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator Maverick Therapeutics
- Developer Takeda
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer